MacroGenics | MGNX - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.29B 73M 2026-06
Amgen USD 1.87B 271M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
Biogen USD 945.1M 147.6M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Daiichi Sankyo JPY 124.29B 6.02B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Genmab DKK 84M 19M 2026-06
Geron USD 1.69M 386K 2026-03
Gilead Sciences USD 1000M 445M 2026-06
J&J USD 8B 67M 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
MacroGenics USD 9.53M 585K 2026-03
Merck USD 3.14B 200M 2026-06
Pfizer USD 4.09B 498M 2026-06
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Xencor USD 61.66M 50.95M 2025-06